-
Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)
Thursday, February 28, 2013 - 4:13pm | 841Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of February. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN) and Vertex Pharmaceuticals (NASDAQ: VRTX) grew somewhat between the January 31...
-
Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)
Tuesday, February 12, 2013 - 2:29pm | 829Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the latter two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX) and VIVUS...
-
Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)
Saturday, January 26, 2013 - 1:17pm | 836Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...
-
Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)
Friday, December 28, 2012 - 12:10pm | 823Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...
-
Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)
Wednesday, December 12, 2012 - 1:57pm | 828Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...
-
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Monday, November 12, 2012 - 2:24pm | 844Read More...The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...
-
Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)
Thursday, October 25, 2012 - 2:09pm | 847Read More...The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ...
-
Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)
Monday, October 15, 2012 - 6:59am | 826Read More...After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September. Shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx...
-
Short Sellers Shy Away from Biotech Firms
Thursday, September 13, 2012 - 1:34pm | 575Read More...The short interest data is out from the August 31 settlement date. By and large short sellers have retreated from gambles on biotech firms, compared to the August 15 settlement date. A few notable exceptions were Amgen (NASDAQ: AMGN), for which short interest was higher by 8.8 percent to 12.8...
-
Short Interest in Biotech Firms on the Rise
Monday, August 27, 2012 - 3:21pm | 571Read More...Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date. A couple of notable exceptions are Alexion Pharmaceuticals (NASDAQ: ALXN) and Biogen Idec (NASDAQ: BIIB), which saw short...
-
Dendreon, Pharmacyclics and Other Biotech Takeover Targets
Tuesday, July 10, 2012 - 2:07pm | 806Read More...M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...
-
Oppenheimer Reviews Arena Pharmaceuticals at the Quarter
Wednesday, August 10, 2011 - 6:50am | 106Read More...Oppenheimer has published a report on Arena Pharmaceuticals (NASDAQ: ARNA) reviews numbers at the second quarter. In the report, Oppenheimer wrote, "On 8/9, ARNA reported 2Q results. Regarding lorcaserin for obesity, ARNA/Eisai expect to file a CRL response with the FDA by YE11 and an EU MAA in...
-
Oppenheimer Raises EPS Estimate From $0.58 To $0.69 On ARNA
Wednesday, May 11, 2011 - 7:27am | 84Read More...In a recent report, Oppenheimer has raised the EPS estimate on Arena Pharmaceuticals (NASDAQ: ARNA) from $0.58 to $0.69 and continues to see obstacles for the Lorcasserin approval. In the report, Oppenheimer said, "ARNA plans to conduct 3 mo. preclinical trials to resolve this key issue, notably...
-
Hapoaliom Views Arena's Lorcaserin As Unapprovable
Thursday, December 23, 2010 - 10:12am | 233Read More...Hapoalim Securities has published a research report on Arena Pharmaceuticals (NASDAQ: ARNA) after the company completed its End of Review meeting with the FDA concerning Lorcaserin. In the report, Hapoalim Securities writes "Arena announced that it has completed the planned Type A (End of Review)...
-
Arena Waiting On FDA Approval Of Lorcaserin
Wednesday, November 10, 2010 - 9:09am | 179Read More...Jefferies & Co. has published a research report on Arena Pharmaceuticals (NASDAQ: ARNA) that expressed concern about the approval of lorcaserin. In the report, Jefferies writes "ARNA's primary goal at the moment is obtaining FDA approval. They plan to meet with FDA before the end of the year to...
